| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000012196 |
| Receipt No. | R000013206 |
| Official scientific title of the study | The Study on HElicobacter Pylori eradication in patients with HEPatic complications |
| Date of disclosure of the study information | 2019/03/31 |
| Last modified on | 2016/11/09 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | The Study on HElicobacter Pylori eradication in patients with HEPatic complications | |
| Title of the study (Brief title) | HepHep Study | |
| Region |
|
|
| Condition | ||||
| Condition | Chronic liver diseases
H. pylori infection |
|||
| Classification by specialty |
|
|||
| Classification by malignancy | Others | |||
| Genomic information | NO | |||
| Objectives | |
| Narrative objectives1 | To clarify whether eradication of H. pylori in patients with chronic liver disease affects the hepatic complications such as thrombocytopenia and hyperammonemia |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Changes in platelet counts after eradication of H. pylori |
| Key secondary outcomes | Changes in blood ammonia levels after eradication of H. pylori |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Patients will orally receive triple therapy with 30mg lansoprazole, 750mg amoxicillin, and 250mg clarithromycin twice a day for seven days | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Patients with chronic liver diseases
2. Patients with hepatic complications such as thrombocytopenia and hyperammonemia 3. Patients with H. pylori-related atrophic gastritis other upper gastrointestinal diseases diagnosed endoscopy |
|||
| Key exclusion criteria | 1. Patients with history of hypersensitivity to lansoprazole, amoxicillin, and clarithromycin.
2. Patients being treated with atazanavir, rilpivirine, pimozide, preparation containing ergotamine and tadalafil. 3. Patients with liver or kidney diseases being treated with colchicine. 4. Patients with infectious mononucleosis. 5. Patients with severe renal impairment. 6. Woman during the first three months of pregnancy. 7. Patients whom the principal and/or sub-investigators judged inadequate. |
|||
| Target sample size | 30 | |||
| Research contact person | |
| Name of lead principal investigator | Masaru Enomoto |
| Organization | Osaka City University Graduate School of Medicine |
| Division name | Department of Hepatology |
| Address | 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan |
| TEL | 06-6645-3811 |
| enomoto-m@med.osaka-cu.ac.jp | |
| Public contact | |
| Name of contact person | Masaru Enomoto |
| Organization | Osaka City University Graduate School of Medicine |
| Division name | Department of Hepatology |
| Address | 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan |
| TEL | 06-6645-3811 |
| Homepage URL | |
| enomoto-m@med.osaka-cu.ac.jp | |
| Sponsor | |
| Institute | Osaka City University Graduate School of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000013206 |